NuGEN Launches 2 New Products: The Ovation(TM) Whole Blood Solution and the Ovation(TM) RNA Amplification System V2.

Built on NuGEN's Proprietary SPIA[TM] Technology for Gene Expression Analysis of Small and Challenging Samples; Enabling Amplification and Analysis of RNA From Whole Blood without the Need for Globin Reduction

SAN CARLOS, Calif. -- NuGEN, Technologies, Inc., a privately held company that develops and commercializes the standard in nucleic acid amplification and labeling systems for small and difficult samples, today announced the release of a modular amplification system for RNA from any source, and a modular solution for amplification of RNA isolated from whole blood, allowing analysis on the Affymetrix GeneChip[R] without the need for globin reduction. These products follow closely on NuGEN's September 18th launch of WT-Ovation[TM] Pico RNA Amplification System and the FL-Ovation[TM] cDNA Biotin Module V2, highlighting the rapidly growing market acceptance of the NuGEN Ovation[TM] System family of products as the gold standard for amplification and target preparation for differential expression analysis of small and difficult samples and high throughput applications.

The new Ovation[TM] RNA Amplification System V2 replaces the Ovation[TM] RNA Biotin Amplification and Labeling System when used in conjunction with FL-Ovation[TM] cDNA Biotin Module V2. The modular system offers flexibility, is especially well suited for automation, and yields micrograms of amplified cDNA in under 4 hours for qPCR and for fragmentation and labeling for microarray analysis.

NuGEN is also launching the Ovation[TM] WB Reagent for the Ovation[TM] Whole Blood Solution. This product is part of a solution that includes two other NuGEN products, enabling gene expression analysis of as little as 20 nanograms of whole blood RNA on GeneChip[R] arrays in just one day, without the need for Globin reduction,. "The Whole Blood Solution enables amplification of small amounts of RNA from whole blood rapidly and cleanly," said Garry Miyada, vice president of development at NuGEN. "The cDNA generated by this process is obtained with fewer sample manipulations than alternative approaches, and affords excellent results on GeneChip[R] microarrays."

"NuGEN continues to expand accessibility to increasing numbers of sample types for scientists carrying out differential gene expression research," said Sue Pandey, vice president of commercial operations for NuGEN. "The launch of these products demonstrates our commitment to meet the challenges facing today's discovery and clinical research laboratories in high throughput gene expression analysis."

For pricing and availability information for the Ovation[TM] RNA Amplification System V2 (Cat.#3100) and the Ovation[TM] WB Reagent (Cat.# 1300), please contact NuGEN Technologies at 888-654-6544 or [e-mail], or visit NuGEN's website at www.nugeninc.com.

About NuGEN Technologies Inc.

NuGEN Technologies is focused on the development and commercialization of sensitive, rapid and cost-effective amplification and detection systems for genomic and proteomic research. The company's technologies enable the comprehensive analysis and discovery of biological mechanisms, cellular responses, and disease pathologies. NuGEN's proprietary SPIA([TM]) and Ribo-SPIA([TM]) amplification and labeling system for DNA and RNA based applications, form the foundation for a wide range of methods and products used by life scientists. The Ovation([TM]) amplification and labeling system, the company's first commercially available product line, has applied these technologies to enhancing the sensitivity, convenience, and accuracy of gene expression analysis. Based in San Carlos, CA, NuGEN has a world-class investor syndicate, several collaborations with leading academic and commercial organizations and a management team with significant experience developing and marketing products for research or clinical diagnostic applications.

NuGEN, Ovation, SPIA, Ribo-SPIA, WT-Ovation, FL-Ovation, and Imagine More From Less are trademarks or service marks of NuGEN Technologies, Inc. All other marks are the property of their respective owners.

This press release contains forward-looking statements that are subject to risks and uncertainties, including continued growth in demand by researchers for total RNA analysis, continued use of oligo and cDNA microarrays, acceptance by researchers of the Company's technologies and products, and competition from existing and newly developed products. Accordingly, actual results may differ materially from those anticipated. These forward-looking statements represent the Company's current expectations as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.